

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 1647
Examiner Name	G. Bensal NICHOLS
Attorney Docket Number	SOLOMON=1R

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

7 | 30 | 2003

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	2	of	2
-------	---	----	---

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 1647
Examiner Name	G. Benson NICHOLS
Attorney Docket Number	SOLOMON=1R

[illegible]

6 miles

7/30/03

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	4642-1647
Examiner Name	G. Bancal NICHOLS
Attorney Docket Number	SOLOMON=1R

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CSO	AE	5,750,349	A	Suzuki et al	05-12-1998	
	AF	5,753,624	A	McMichael et al	05-19-1998	
	AG	5,851,996	A	Kline	12-22-1998	
CSO	AH	5,955,317	A	Suzuki et al	09-21-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
CSO	AI	WO	95/31996	A1 MILKHAUS LABORATORY	11-30-1995	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CSO	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)	
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)	
	AL	JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)	
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)	
	AN	MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)	
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)	
	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)	
CSO	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", March 2002 (www.elan.com/NewsRoom)	

Examiner
Signature

G. Nichols

Date
Considered

7/30/02 TECH CENTER 600/2900

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known


Attorney Docket Number	SOLOMON=1R
------------------------	------------

Sheet	1	of	8
-------	---	----	---

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
ESD	AR	6,417,178	B1	Klunk et al	07-09-2002	
	AS	6,284,221	B1	Schenk et al	09-04-2001	
	AT	6,262,335	B1	Hsiao et al	07-17-2001	
	AU	6,114,133	-	Seubert et al	09-05-2000	
	AV	5,958,883	-	Snow	09-28-1999	
	AW	5,955,079	-	Mond et al	09-21-1999	
	AX	5,877,399	-	Hsiao et al	03-02-1999	
	AY	5,869,093	-	Weiner et al	02-09-1999	
	AZ	5,869,054	-	Weiner et al	02-09-1999	
	BA	5,849,298	-	Weiner et al	12-15-1998	
	BB	5,837,473	-	Maggio et al	11-17-1998	
	BC	5,780,587	-	Potter	07-14-1998	
	BD	5,744,368	-	Goldgaber et al	04-28-1998	
	BE	5,736,142	-	Sette et al	04-07-1998	
	BF	5,733,547	-	Weiner et al	03-31-1998	
	BG	5,679,348	-	Nesburn et al	10-21-1997	
	BH	5,645,820	-	Hafler et al	07-08-1997	
	BI	5,641,474	-	Hafler et al	06-24-1997	
	BJ	5,641,473	-	Hafler et al	06-24-1997	
	BK	5,612,486	-	McConlogue et al	03-18-1997	
BL	5,605,811	-	Seubert et al	02-25-1997		
BM	5,585,100	-	Mond et al	12-17-1997		
BN	5,571,500	-	Hafler et al	11-05-1996		
BO	5,571,499	-	Hafler et al	11-05-1996		
BP	5,441,870	-	Seubert et al	08-15-1995		
BQ	5,434,170	-	Andrulis, Jr.	07-18-1995		
BR	5,387,742	-	Cordell	02-07-1995		
BS	5,270,165	-	Van Nostrand et al	12-14-1993		
BT	5,231,170	-	Averback	07-27-1993		
BU	5,231,000	-	Majocha et al	07-27-1993		
BV	5,220,013	-	Ponte et al	06-15-1993		
BW	5,208,036	-	Eppstein et al	05-04-1993		
BX	5,192,753	-	McGeer et al	03-09-1993		
BY	5,187,153	-	Cordell et al	03-09-1993		
BZ	5,057,540	-	Kensil et al	10-15-1991		
CA	5,004,697	-	Partridge	04-20-1991		
CB	4,666,829	-	Glenner et al	05-19-1987		

7/30/03

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 1647
Examiner Name	S. Unger NICHOLS
Attorney Docket Number	SOLOMON=1R

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number	Kind Code ⁵ (if known)				
G	CC	WO	94/28412	A1	The Miriam Hospital	12-08-1994		
	CD	WO	94/03615	A1	Medeva Holdings B.V.	02-17-1994		
	CE	WO	94/01772	A1	Children's Med. Cen. Corp.	01-20-1994		
	CF	EP	0 276 723	B1	Bayer AG	12-08-1993		Yes
	CG	WO	93/21950	A1	Medeva Holdings B.V.	11-11-1993		
	CH	WO	93/16724	A1	Autoimmune, Inc.	09-02-1993		
	CI	WO	93/15760	A1	Mond et al	08-19-1993		
	CJ	WO	93/14200	A1	TSI Corporation	07-22-1993		
	CK	WO	93/04194	A1	Regents of U. of Minn.	03-04-1993		
	CL	WO	93/02189	A1	Regents of U. of Cal.	02-04-1993		
	CM	WO	92/13069	A1	Imp. Col. of Sci, Tech. & Med.	08-06-1992		
	CN	WO	92/06708	A1	Brigham and Women's Hosp.	04-30-1992		
	CO	WO	92/06187	A1	The Upjohn Company	04-16-1992		
	CP	WO	91/19810	A1	California Biotechnology Inc.	12-26-1991		
	CQ	WO	91/16819	A1	Molecular Rx, Inc.	11-14-1991		
	CR	EP	0 451 700	A1	Miles Inc.	10-16-1991		
	CS	WO	91/12816	A1	Autoimmune, Inc.	09-05-1991		
	CT	WO	91/08760	A1	Brigham and Women's Hosp.	06-27-1991		
	CU	WO	90/12871	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
	CV	WO	90/12870	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990		
CW	GB	2 220 211	A	Ribi Immunochem Research Inc.	01-04-1990			
CX	WO	89/06689	A1	McLean Hosp. Corp. & U. Roch.	07-27-1989			
CY	WO	89/06242	A1	McLean Hosp. Corp. & U. Roch.	07-13-1989			
CZ	WO	89/03687	A1	Genetics Institute, Inc.	05-05-1989			
DA	WO	89/01343	A1	Regents of U. of Cal.	02-23-1989			
DB	WO	88/10120	A1	Brigham and Women's Hosp.	12-29-1988			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
G	DC	BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J Mol Biol</i> 225(4):1075-1093 (1992)	


Examiner
Signature

Date
Considered

11/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	4042 1647
		Examiner Name	S. Ungar DICHOLS
Sheet 3 of 8	Attorney Docket Number	SOLOMON=1R	

DD	BAUER et al, "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Lett</u> 285(1):111-114 (1991)
DE	BICKEL et al, "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc for Neuroscience Abstracts</u> 18:764 (325.6) (1992)
DF	BODMER et al, "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem Biophys Res Comm</u> 171(2):890-897 (1990)
DG	BORIS-LAWRIE et al, "Recent advances in retrovirus vector technology," <u>Curr Opin Genet Dev</u> 3(1):102-109 (1993)
DH	BRICE et al, "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J Neurol Neurosurg Psychiatry</u> 56:112-113 (1993)
DI	CAPUTO et al, "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin Neuropharm</u> 15(S1):414A-415A (1992)
DJ	CHAO et al, "Transforming Growth Factor- β Protects Human Neurons Against β -Amyloid-Induced Injury," 23 rd Annual Meeting, Washington, DC, November 7-12, 1993, <u>Soc Neurosci Abstracts</u> 19:513.7 (1993)
DK	CHEN et al "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neurosci Lett</u> 125(2):223-226 (1991)
DL	CORDELL B β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>An. Rev Pharmacol Toxicol</u> 34:69-89 (1994)
DM	COSTA et al, "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand J Immunol</u> 38:177-182 (1993)
DN	ELIZAN et al, "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J Neurol Sci</u> 59(3):341-347 (1983)
DO	FELSENSTEIN et al, "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neurosci Lett</u> 152:185-189 (1993)
DP	FISHER et al, "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>Proc Natl Acad Sci</u> 88:1779-1782 (1991)
DQ	GANDY et al, "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> 13:108-113 (1992)

Examiner Signature		Date Considered	7/30/03
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



RECEIVED

NOV 15 2002

TECH CENTER 1600

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642-1677
Examiner Name	S. Ungar NICHOLS
Attorney Docket Number	SOLOMON=1R


DR	GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990)
DS	GASKIN et al, "Human antibodies reactive with β -amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993)
DT	GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 122(3):885-890 (1984)
DU	GLENNER et al, "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984)
DV	GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> 349:704-706 (1991)
DW	GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949)
DX	HAASS et al "Amyloid β -peptide is produced by cultured cells during normal metabolism," <u>Nature</u> 359(6393):322-5 (1992)
DY	HAGA et al, "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993)
DZ	HARRINGTON et al, "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993)
EA	HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2", <u>Immunology</u> 78:643-649 (1993)
EB	HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991)
EC	HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J Neuroimmunol</u> 52(2):147-152 (1994)
ED	IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987)
EE	ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989)

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 .of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	7042-1647
Examiner Name	S. Ungar
Attorney Docket Number	SOLOMON=1R

TECH CENTER
NOV 16 2002
RECEIVED**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GO	EF	WATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> 13:45-53 (1994)	
	EG	JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immunol Rev</u> 62:185-216 (1982)	
	EH	JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am J Pathol</u> 138(2):373-384 (1991)	
	EI	KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res Immunol</u> 143:637-641 (1992)	
	EJ	KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> 354:476-478 (1991)	
	EK	LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993)	
	EL	LANGER, "New Methods of Drug Delivery," <u>Science</u> 249:1527-1532 (1990)	
	EM	LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993)	
	EN	LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991)	
	EO	MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nuc Med</u> 33:2184-2189 (1992)	
	EP	MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994)	
GO	EQ	MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985)	

Examiner
SignatureDate
Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/57 (10/96)

